Abstract:BackgroundWith an estimated 249 million cases and 608,000 deaths in 2022 malaria continues to cause substantial morbidity and mortality worldwide, mostly in children in Sub-Saharan Africa due to Plasmodium falciparum . Circumsporozoite protein (CSP) coats the surface of the P. falciparum sporozoite and is the target of the two vaccines approved by the World Health Organization (WHO). CSP has three major regions: the N-terminus, the central repeat region, and the C-terminus, which contains highly variable T cell epitopes; only a fragment of the central repeat region and the C-terminus are represented by the two approved vaccines. The junction between the N-terminal Region 1 and the NANP repeat region ("junctional region") is not represented in the approved vaccines and was recently found to be a target of protective antibody responses.MethodsWe used a repetitive controlled human malaria infection (rCHMI) model in which eight malaria-naïve participants were infected with P. falciparum up to three times over two years to identify immune responses associated with acquisition of natural immunity. We evaluated samples from the day of each CHMI and 18 days after each CHMI. We measured antibody responses using a peptide microarray inclusive of hundreds of P. falciparum proteins and focused our current study on the response to CSP. The amino acid sequences of CSP from the NF54 strain and 4 additional CSP variants were represented as 16-amino acid peptides with 13-amino acid overlap. Signal intensities at each amino acid position were estimated using a sliding window approach that averaged signals from adjacent overlapping peptides. Participants who comprised a "delayed parasitemia group" (n = 5) had onset of PCR-confirmed parasitemia 13 or more days after the last CHMI, a sign of developing humoral immunity. A "non-delayed parasitemia group" (n = 3) was comprised of those had onset of parasitemia within 12 or fewer days after the last CHMI. Along each amino acid position, the median signal intensities for all CSP variants are presented to describe the participants' antibody responses at each time point. Wilcoxon signed rank test was used to compare medians between timepoints; p-values < 0.05 without adjustment for multiple comparisons were considered statistically significant.ResultsAfter three rCHMIs, participants developed antibody responses to amino acids corresponding to the junctional region and the central repeat region (P<0.05). When participants are grouped by time to parasitemia, those who showed delayed parasitemia development had strong immune responses to the junctional region while the non-delayed group did not. Antibody responses to the C-terminal region were more variable among the 5 CSP variant sequences compared to other regions.ConclusionOur results showed higher junctional region antibody response in participants with delayed time to parasitemia. We also demonstrate variable antibody response to the C-terminal region, a region with known greater genetic variability that has been previously associated with allele-specific vaccine escape and concern for decreased efficacy of current WHO-approved vaccines. Taken together, our results support future vaccine development that focuses on the conserved junctional region over the polymorphic C-terminal region.

Modelling the within-host dynamics of hypnozoite activation: an analysis of the SPf66 vaccine trial

An activation-clearance model for Plasmodium vivax malaria

Hypnozoite dynamics for Plasmodium vivax malaria: The epidemiological effects of radical cure

Number and proportion of P. falciparum gametocytes vary from acute infection to chronic parasite carriage despite unaltered sexual commitment rate

Constant rate of Plasmodium falciparum sexual commitment promotes variable gametocyte proportions as infection progresses over time

Treatment of Chronic Asymptomatic Plasmodium Falciparum Infection Does Not Increase the Risk of Clinical Malaria Upon Reinfection

Increased Circulation Time of Plasmodium Falciparum Underlies Persistent Asymptomatic Infection in the Dry Season

Exposure-Dependent Control of Malaria-Induced Inflammation in Children

Dendritic cell responses to Plasmodium falciparum in a malaria-endemic setting

A hybrid transmission model for Plasmodium vivax accounting for superinfection, immunity and the hypnozoite reservoir

Optimal interruption of P. vivax malaria transmission using mass drug administration

Superinfection and the hypnozoite reservoir for Plasmodium vivax: a general framework

Investigation of P. vivax elimination via mass drug administration: A simulation study

The empirical support for the radical cure strategy for eliminating Plasmodium vivax in China

Investigation of P. Vivax Elimination via Mass Drug Administration

Mass Spectrometry Identification of Biomarkers in Extracellular Vesicles From Plasmodium vivax Liver Hypnozoite Infections

Developing sero-diagnostic tests to facilitate Plasmodium vivax Serological Test-and-Treat approaches: modeling the balance between public health impact and overtreatment

Optimization of an in vivo model to study immunity to Plasmodium falciparum pre-erythrocytic stages

Hyper-diverse antigenic variation and resilience to transmission-reducing intervention in falciparum malaria

Microhaplotype deep sequencing assays to capture infection lineages

The Progression of Epitope-specific Antibody Responses toPlasmodium falciparum Circumsporozoite Protein Following Consecutive Malaria Infections in Naïve Adults: A Repetitive Controlled Human Malaria Infection Study